| |
|
|
|
|
|
 |
| |
|
±Û·çŸ¼ÖÁÖ 500mL(¹é) Glutasol Infu 500
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644900412
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/500mL/¹é(2021.11.01)(ÇöÀç¾à°¡)
\17,808 ¿ø/500mL/¹é(2018.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
À¯¸®¿ë±â ¶Ç´Â Æú¸®ÇÁ·ÎÇÊ·»Á¦ ¼ö¼ºÁÖ»çÁ¦ ¿ë±â¿¡ µç ¹«»ö ³»Áö ¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
500mL/¹é |
| ÁÖ¼ººÐÄÚµå |
422400BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
°æ±¸ ¶Ç´Â À§Àå°ü ¿µ¾çº¸±ÞÀÌ ºÒ°¡´É ¶Ç´Â ºÒÃæºÐÇϰųª ±Ý±âÀΠȯÀڵ鿡°Ô ƯÈ÷ Áߵ ³»Áö ½É°¢ÇÑ ÀÌÈ»óÅÂÀÇ È¯Àڵ鿡°Ô ¾Æ¹Ì³ë»êÀ» º¸±Þ.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
- Åõ¿©·® : 1ÀÏ Ã¼Áß kg´ç ÃÑ ¾Æ¹Ì³ë»ê/µðÆéƼµå·Î¼ 1~2g(Áú¼Ò·Î¼ 0.17~0.34g)À» ÁüÀûÁ¤ÁÖÇÑ´Ù. ÀÌ´Â ÀÌ ¾àÀ¸·Î¼ 1ÀÏ Ã¼Áß kg ´ç 7~14mL¿¡ ÇØ´çÇϸç, üÁß 70kgÀΠȯÀÚÀÇ °æ¿ì 1ÀÏ 500~1000mL¸¦ Åõ¿©ÇÑ´Ù.
- Åõ¿©¼Óµµ : üÁß kg ´ç 1½Ã°£µ¿¾È 0.6 ~ 0.7 mL(ÃÑ ¾Æ¹Ì³ë»ê / µðÆéƼµå·Î¼ 0.08~0.09 g) °¡ ¹Ù¶÷Á÷ÇÏ´Ù.
|
| ±Ý±â |
1) ¼±Ãµ¼º ¾Æ¹Ì³ë»ê ´ë»ç ÀÌ»ó ȯÀÚ(Æä´ÒÄÉÅæ´¢Áõ µî)
2) ÁßÁõÀÇ °£ºÎÀü, ½ÅºÎÀü ȯÀÚ
3) ºÒ¾ÈÁ¤ÇÏ¸ç »ý¸íÀ» À§ÇùÇÏ´Â ¼øÈ¯°èÀÇ ÀÌ»ó(¼ï)ȯÀÚ
4) ´ë»ç¼º »êÁõ ȯÀÚ
5) ¼¼Æ÷»ê¼Ò°ø±Þ ºÎÁ·, ¼öºÐ °ú´Ù °ø±ÞÀÌ Àִ ȯÀÚ
6) Àú³ªÆ®·ýÇ÷Áõ ȯÀÚ, ÀúÄ®·ýÇ÷Áõ ȯÀÚ
7) °íÁ¥»êÇ÷Áõ ȯÀÚ
8) Ç÷û »ïÅõ¾ÐÀÌ Áõ°¡µÈ ȯÀÚ
9) ÆóºÎÁ¾ ȯÀÚÇ÷
10) ´ë»óºÎÀü¼º ½ÉºÎÀü ȯÀÚ
11) ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¹ÝÀÀÀÌ Àִ ȯÀÚ
12) 2¼¼ ÀÌÇÏÀÇ ¿µ¾Æ
13) ½É±Ù°æ»ö ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¿Ã¹Ù¸£°Ô Åõ¿© ½Ã ÀÌ»ó¹ÝÀÀÀº ¾Ë·ÁÁöÁö ¾Ê¾Ò´Ù.
2) ±Þ¼ÓÅõ¿© ½Ã ºÒ°ü¿ë(intolerance)Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ¿ÀÇÑ, ±¸¿ª, ±¸Åä, È«Á¶ ¹ßÇÑ ¹× ¾Æ¹Ì³ë»ê°ú µðÆéƼµåÀÇ ½ÅÀå¹è¼³ Áõ»óÀÌ ¹ßÇöµÉ ¼ö ÀÖ´Ù. ÀÌ °æ¿ì¿¡´Â Åõ¿©¼Óµµ¸¦ ÁÙÀ̰ųª Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
3) ÀϽÃÀûÀÎ °£È¿¼Ò »ó½ÂÀ¸·Î ÀÎÇÑ ¼³»ç, µÎÅë, ¸¶ºñ, ü¿Â»ó½Â, °¡·Á¿ò, ¿°¨ µîÀÇ Áõ»óÀ» º¸ÀÏ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
Áö±Ý±îÁö ¾Ë·ÁÁø »óÈ£ÀÛ¿ëÀº ¾ø´Ù. |
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: ARGININER-GENE 10 (ARGININE HYDROCHLORIDE)
±âÁØ ¼ººÐ: ALANINE
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Glutamine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Pharmacokinetics |
Glutamic acidÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ºÐÆ÷ : ´ëºÎºÐÀÌ °ñ°Ý±Ù¿¡¼ ÇÕ¼ºµÇ°í ÀúÀåµÈ´Ù.
MethionineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : S-adenosylmethionineÀ» °ÅÃÄ homocysteineÀ¸·Î ÀüȯµÈ´Ù. ±× ÈÄ 80%°¡ cystathione, cysteine, taurine, inorganic sulphate·Î Á¡Â÷·Î ´ë»çµÈ´Ù.
ArginineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ°í Ç÷Áß³óµµ µµ´Þ : °æ±¸ : 2½Ã°£
- ÃÖ´ë È¿°ú ¹ßÇö :
- ´ç´¢ Áø´Ü : Á¤¸ÆÁÖ»ç : 20-45 ºÐ
Ç÷´çÀÇ ÃÖ°í »ó½ÂÀº 20ºÐ ÈÄ¿¡ ³ªÅ¸³ª¸ç, Àν¶¸°ÀÇ ÃÖ´ë »ó½ÂÀº 20-30 ºÐ ÈÄ¿¡ ³ªÅ¸³ª¸ç glucagonÀº 30-45 ºÐ ÈÄ¿¡ ³ªÅ¸³´Ù.
- ¼ºÀåÈ£¸£¸ó º¸À¯ Áø´Ü : Á¤¸ÆÁÖ»ç : 1-2 ½Ã°£
Arginine 30 gÀ» 30ºÐ°£ Á¤¸ÆÁÖ»ç ÈÄ ¼ºÀåÈ£¸£¸óÀÇ ÃÖ´ë »ó½ÂÀÌ ¾à 1-2 ½Ã°£ ÈÄ¿¡ ³ªÅ¸³´Ù.
- ÀÛ¿ë Áö¼Ó ½Ã°£ : Á¤¸ÆÁÖ»ç : 1½Ã°£
- Èí¼ö : À§Àå°ü¿¡¼ Àß Èí¼öµÊ
- ´ë»ç : °£¿¡¼ arginase¿¡ ÀÇÇØ guanidino groupÀÌ °¡¼öºÐÇØµÇ¾î urea¿Í ornithineÀ» »ý¼ºÇÑ´Ù.
OrnithineÀº ±Ã±ØÀûÀ¸·Î glucose »ý¼º¿¡ ÀÌ¿ëµÈ´Ù.
- ¼Ò½Ç : ½ÅÀå : »ç±¸Ã¼·Î ¿©°úµÇ°í ½Å¼¼´¢°üÀ¸·Î ÀçÈí¼öµÈ´Ù.
- ¹Ý°¨±â : 1.2-2 ½Ã°£
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug-Induced Toxicity Related Proteins |
GLUTAMINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Latent transforming growth factor beta-binding protein, isoform 1L Drug:glutamine Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:Glucosamine--fructose-6-phosphate aminotransferase Drug:glutamine Toxicity:arrest cellular proliferation . [¹Ù·Î°¡±â] Replated Protein:Epidermal growth factor receptor Drug:glutamine Toxicity:arrest cellular proliferation . [¹Ù·Î°¡±â] Replated Protein:Glucosamine--fructose-6-phosphate aminotransferase Drug:glutamine Toxicity:apoptosis. [¹Ù·Î°¡±â] LYSINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [¹Ù·Î°¡±â] METHIONINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [¹Ù·Î°¡±â] Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â] Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-01-26
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|